{
  "symbol": "MRK",
  "year": 2023,
  "Period": "Q2",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.2041,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.09
  },
  "top_positive": [
    {
      "sent": "Unregistered Sales of Equity Securities and Use of Proceeds Issuer purchases of equity securities for the three months ended June\u00a030, 2023 were as follows: ISSUER PURCHASES OF EQUITY SECURITIES ($\u00a0in\u00a0millions) Period Total\u00a0Number of Shares Purchased (1) Average\u00a0Price Paid Per Share Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs Approximate\u00a0Dollar\u00a0Value\u00a0of\u00a0Shares That May Yet Be Purchased Under the Plans or Programs (1) April 1 - April 30 376,898 $110.51 376,898 $4,856 May 1 - May 31 907,404 $114.76 907,404 $4,752 June 1 - June 30 1,734,532 $110.72 1,734,532 $4,560 Total 3,018,834 $111.91 3,018,834 (1) Shares purchased during the period were made as part of a plan approved by the Board of Directors in October 2018 to purchase up to $10 billion of Merck\u2019s common stock for its treasury.",
      "score": 0.968
    },
    {
      "sent": "These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development.",
      "score": 0.9451
    },
    {
      "sent": "These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development.",
      "score": 0.9451
    }
  ],
  "top_negative": [
    {
      "sent": "Phase 2 Cancer MK-0482 (2) Non-Small-Cell Lung MK-1308 (quavonlimab) (2) Non-Small-Cell Lung MK-1308A (quavonlimab+pembrolizumab) Colorectal Hepatocellular Melanoma Small-Cell Lung MK-2140 (zilovertamab vedotin) Bladder Breast Gastric Hematological Malignancies Non-Small-Cell Lung Ovarian Pancreatic MK-2870 (1)(3) Neoplasm Malignant MK-3475 Keytruda Advanced Solid Tumors Prostate MK-3543 (bomedemstat) Myeloproliferative Disorders MK-4280 (favezelimab) (2) Non-Small-Cell Lung MK-4280A (favezelimab+pembrolizumab) Bladder Esophageal Melanoma Renal Cell Small-Cell Lung MK-4830 (2) Colorectal Esophageal Melanoma Non-Small-Cell Lung Ovarian Renal Cell Small-Cell Lung Cancer MK-5684 (1) Prostate MK-5890 (boserolimab) (2) Non-Small-Cell Lung Small-Cell Lung MK-6482 Welireg (3) Biliary Colorectal Endometrial Esophageal Hepatocellular Pancreatic Rare cancers Von Hippel-Lindau Disease-Associated Tumors (EU) MK-7119 Tukysa (1) Advanced Solid Tumors Biliary Bladder Cervical Endometrial Gastric Non-Small-Cell Lung MK-7339 Lynparza (1)(3) Advanced Solid Tumors MK-7684A (vibostolimab+pembrolizumab) Biliary Bladder Breast Cervical Colorectal Endometrial Esophageal Gastric Head and Neck Hematological Malignancies Hepatocellular Ovarian Prostate Cancer MK-7902 Lenvima (1)(2) Biliary Pancreatic Prostate Small-Cell Lung Dengue Fever Virus Vaccine V181 HIV-1 Infection MK-8591B (islatravir+MK-8507) (4) MK-8591D (islatravir+lenacapavir) (1)(5) Hypercholesterolemia MK-0616 Nonalcoholic Steatohepatitis (NASH) MK-6024 (efinopegdutide) Pulmonary Arterial Hypertension MK-5475 Pulmonary Hypertension Due To Left Heart Disease MK-7962 (sotatercept) Schizophrenia MK-8189 (6) Thrombosis MK-2060 Treatment Resistant Depression MK-1942 Ulcerative Colitis MK-7240 - 40 - Phase 3 (Phase 3 entry date) Under Review Antiviral COVID-19 MK-4482 Lagevrio (U.S.) (May 2021) (1)(7) Cancer MK-1026 (nemtabrutinib) Hematological Malignancies (March 2023) MK-1308A (quavonlimab+pembrolizumab) Renal Cell (April 2021) MK-3475 Keytruda Cutaneous Squamous Cell (August 2019) (EU) Hepatocellular (May 2016) (EU) Mesothelioma (May 2018) Ovarian (December 2018) Small-Cell Lung (May 2017) MK-3475A (pembrolizumab+hyaluronidase subcutaneous) Non-Small-Cell Lung (February 2023) MK-4280A (favezelimab+pembrolizumab) Colorectal (November 2021) Hematological Malignancies (October 2022) MK-6482 Welireg (3) Renal Cell (February 2020) MK-7119 Tukysa (1) Breast (October 2019) Colorectal (August 2022) MK-7339 Lynparza (2) Non-Small-Cell Lung (June 2019) Small-Cell Lung (December 2020) MK-7684A (vibostolimab+pembrolizumab) Melanoma (January 2023) Non-Small-Cell Lung (April 2021) Small-Cell Lung (March 2022) MK-7902 Lenvima (1)(2) Esophageal (July 2021) Gastric (December 2020) Head and Neck (February 2020) Non-Small-Cell Lung (March 2019) V940 (1)(2) Melanoma (July 2023) HIV-1 Infection MK-8591A (doravirine+islatravir) (February 2020) (5) Pneumococcal Vaccine Adult V116 (July 2022) Pulmonary Arterial Hypertension MK-7962 (sotatercept) (January 2021) Respiratory Syncytial Virus MK-1654 (clesrovimab) (November 2021) New Molecular Entities Cough MK-7264 (gefapixant) (U.S.) (8) (EU) Certain Supplemental Filings Cancer MK-3475 Keytruda \u2022    Second-Line Hepatocellular Carcinoma (KEYNOTE-394) (U.S.) \u2022    Locally Advanced or Metastatic Merkel Cell Carcinoma (KEYNOTE-913) (U.S.) \u2022    First-Line Advanced or Unresectable Biliary Tract Cancer (KEYNOTE-966) (U.S.) (EU) (JPN) \u2022    First-Line HER2 Negative Locally Advanced Unresectable or Metastatic Gastric Cancer (KEYNOTE-859) (U.S.) (EU) (JPN) \u2022    Resectable Stage II, IIIA or IIIB NSCLC (KEYNOTE-671) (U.S.) (EU) \u2022    Adjuvant Non-Small-Cell Lung Cancer (KEYNOTE-091) (EU) \u2022    Metastatic HER2+ Gastric Cancer (KEYNOTE-811) (EU) MK-7339 Lynparza (1) \u2022    First-Line Metastatic Prostate Cancer (PROpel) (JPN) Footnotes: (1) Being developed in a collaboration.",
      "score": -0.992
    },
    {
      "sent": "These approvals were the result of a broad clinical development program that currently encompasses more than 30 cancer types including: biliary, estrogen receptor positive breast cancer, cervical, colorectal, cutaneous squamous cell, endometrial, esophageal, gastric, glioblastoma, head and neck, hepatocellular, Hodgkin lymphoma, non-Hodgkin lymphoma, non-small-cell lung, small-cell lung, melanoma, mesothelioma, ovarian, prostate, renal, triple-negative breast, and urothelial, many of which are currently in Phase 3 clinical development.",
      "score": -0.7735
    },
    {
      "sent": "AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEET (Unaudited, $ in millions except per share amounts) June 30, 2023 December 31, 2022 Assets Current Assets Cash and cash equivalents $ 5,660 $ 12,694 Short-term investments 718 498 Accounts receivable (net of allowance for doubtful accounts of $ 86 in 2023 and $ 72 in 2022) 11,030 9,450 Inventories (excludes inventories of $ 3,220 in 2023 and $ 2,938 in 2022 classified in Other assets - see Note\u00a07) 5,930 5,911 Other current assets 6,639 7,169 Total current assets 29,977 35,722 Investments 1,214 1,015 Property, Plant and Equipment, at cost, net of accumulated depreciation of $ 18,432 in 2023 and $ 17,985 in 2022 22,231 21,422 Goodwill 21,195 21,204 Other Intangibles, Net 19,665 20,269 Other Assets 10,187 9,528 $ 104,469 $ 109,160 Liabilities and Equity Current Liabilities Loans payable and current portion of long-term debt $ 2,839 $ 1,946 Trade accounts payable 3,442 4,264 Accrued and other current liabilities 13,747 14,159 Income taxes payable 1,489 1,986 Dividends payable 1,877 1,884 Total current liabilities 23,394 24,239 Long-Term Debt 34,072 28,745 Deferred Income Taxes 996 1,795 Other Noncurrent Liabilities 7,265 8,323 Merck\u00a0& Co., Inc.",
      "score": -0.765
    }
  ],
  "forward_snippets": [
    "Recently Adopted Accounting Standards In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance.",
    "The Company adopted the guidance effective January 1, 2023.",
    "The adoption of this guidance did not have an impact on the Company\u2019s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon th\nred by accounting principles generally accepted in the United States (U.S.) (GAAP) for complete consolidated financial statements are not included herein.",
    "Recently Adopted Accounting Standards In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance.",
    "The Company adopted the guidance effective January 1, 2023."
  ]
}